表紙
市場調查報告書

痛風治療藥市場 - 市場佔有率,規模,趨勢,產業分析:2020年∼2026年

Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs, Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition ; By Regions, Segments & Forecast, 2020 - 2026

出版商 Polaris Market Research 商品編碼 953071
出版日期 內容資訊 英文 102 Pages
商品交期: 最快1-2個工作天內
價格
痛風治療藥市場 - 市場佔有率,規模,趨勢,產業分析:2020年∼2026年 Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs, Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition ; By Regions, Segments & Forecast, 2020 - 2026
出版日期: 2020年04月01日內容資訊: 英文 102 Pages
簡介

全球痛風治療藥市場規模,2026年前預計將達到63億480萬美元。痛風的發生率和患病人數在過去20年增加到2倍以上。老年人口的增長和與之相關的患病率的增長是促進產業成長的主要原因。

本報告提供全球痛風治療藥市場相關調查分析,提供市場概要,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 調查手法

第4章 市場分析

  • 概要
  • 痛風治療藥市場動態
  • 波特的五力分析
  • 大環境分析
  • 痛風治療市場產業趨勢
  • 競爭排行榜分析

第5章 痛風治療藥市場評估:各藥物分類

  • 主要調查結果
  • 簡介
  • 非類固醇消炎劑(NSAID)
  • 皮質類固醇
  • 秋水仙鹼
  • 尿酸低墮胎藥

第6章 痛風治療藥市場評估:各病情

  • 主要調查結果
  • 簡介
  • 急性痛風
  • 慢性痛風

第7章 痛風治療藥市場評估:各地區

  • 主要調查結果
  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第8章 競爭情形

  • 契約,聯盟,產品開發,銷售分析
  • 產品/服務的開始
  • 夥伴關係/聯盟/契約
  • 核准
  • 其他

第9章 企業簡介

  • AstraZeneca
  • Horizon Pharma Plc
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co. Inc.
  • Teijin Pharma Limited
  • Regeneron Pharmaceuticals, Inc.
  • Ironwood Pharmaceuticals, Inc.
  • JW Pharmaceutical
  • Selecta Biosciences, Inc.
  • Grunenthal Group
目錄
Product Code: PM1611

Title:
Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition (Acute, Chronic); By Regions, Segments & Forecast, 2020 - 2026.

The global gout therapeutics market size is expected to reach USD 6,304.8 million by 2026 according to a new study by Polaris Market Research. The report "Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition (Acute, Chronic); By Regions, Segments & Forecast, 2020 - 2026" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The incidence and prevalence of gout has increased over two-fold in past 20 years. This growth combined with increasing occurrence of comorbid conditions and cardiovascular risk factors represents a significant public health challenge. Globally, the developed countries tend to have a higher burden of gout compared to the developing countries, and also have increasing prevalence of this disease. There are various factors including genetic history, and ethnicity that could lead to occurrence of gout. Also, socioeconomic and dietary factors, as well as comorbidities and medications that can influence uric acid levels and facilitate MSU crystal formation, are also important in determining the risk of developing clinically evident gout.

Increasing geriatric population, and growing prevalence of this condition associated with this growing elderly population are the primary factors driving the growth of the industry. According to a study published in the Modern Medicine, elder population are more prone to develop tophi and the prevalence of metabolic syndrome among the elder population with gout was 62%. Currently, the geriatric population is growing at an extraordinary rate. According to the data published by the United Nations in 2012, global geriatric population was nearly 809.4 million in 2011 and is anticipated to grow more than double and reach over 2,000 million by 2050.

Furthermore, growing prevalence of this condition across the globe, increasing research and development activities, growing number of product approvals, and increasing public and private investments are some other factors driving the growth of the market during the forecast period. Recently, in New Zealand, the HRC funded Professor Lisa Stamp at the University of Otago to lead the first-ever randomized controlled trial demonstrating an improved dosing strategy using allopurinol to help more patients to manage their gout symptoms. Also, in 2019 researchers at Washington State University Health Sciences Spokane and elsewhere identified a new therapeutic target for the treatment of gout. Such growing research studies are fueling the growth of the market during the forecast period.

However, factors such as patent expiry of blockbuster products, increasing competition in the generic sector and high cost of the newly launched drugs are likely to hinder the growth of this market during the forecast period. The cost associated with gout therapies is poised to increase dramatically due to federal policy decisions and pipeline developments. Also, patent expiry of major blockbuster agents and expected launch of generic version are likely to restrain the growth of the market during the forecast period. Entry of generic after its patent expiry would decline the revenue in future. Hence, high cost of the products and patent expiry of the medicines is a key factor to restrain the growth of the market.

The global market is dominated by North America as the countries such as US and Canada have a large patient base, and also significant number of research activities are being conducted in this region. Many companies operating in this market segment are based in the US, and hence new products are primarily introduced in this regional segment. Gout affects around 8.3 million people in the United States, with prevalence in range of the 1-4%. The prevalence of gout is higher in African Americans as compared to Caucasians, and is projected to be increasing across all demographics in coming few years. Furthermore, government is also taking various measures to generated awareness and provide better healthcare facilities to the patient suffering with gout in this region.

Furthermore, Europe also has a significant share in the global industry. Various international companies have been launching new products in the European market. For instance, in August 2018, Grunenthal received European approval for Duzallo (lesinurad/allopurinol) and extended its gout portfolio. However, Asia-Pacific is projected to witness a fastest growth during the forecast period. This highest growth is mainly anticipated due to the presence of several high economically growing countries such as India, China, South Korea, and other South Asian countries. Increasing number of people linked with smoking and alcohol consumption, growing population, increasing need for effective therapies, and growing expansion of local and international players in this regional segment are also fueling the growth of gout therapeutics market in this region.

The key players in the industry include AstraZeneca, Horizon Pharma Plc, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Teijin Pharma Limited, Regeneron Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and Grunenthal Group among others.

Polaris Market research has segmented the Gout Therapeutics market report on the basis of level, application, material type, product type, product style and region

Gout Therapeutics Drug Class Outlook (Revenue, USD Million, 2015 - 2026)

Non-steroidal Anti-Inflammatory Drugs (NSAIDs)

Corticosteroids

Colchicine

Urate Lowering Agents

Gout Therapeutics Disease Condition Outlook (Revenue, USD Million, 2015 - 2026)

Acute

Chronic

Gout Therapeutics Regional Outlook (Revenue, USD Million, 2015 - 2026)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Belgium

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Australia

Rest of Asia-Pacific

Latin America

Brazil

Mexico

Rest of LATAM

Middle East & Africa

South Africa

Saudi Arabia

Rest of MEA

Table of Contents

Chapter 1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

Chapter 2. Executive Summary

  • 2.1. Market Highlights

Chapter 3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

Chapter 4. Market Analysis

  • 4.1. Overview
  • 4.2. Gout Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing Geriatric Population
      • 4.2.1.2. Increasing incidence and prevalence of gout
      • 4.2.1.3. Growing research and development activities
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of new and improved drugs
      • 4.2.2.2. Patent expiry of various blockbuster drugs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats Of New Entrants: (High)
    • 4.3.3. Bargaining Power Of Buyers (High)
    • 4.3.4. Threats Of Substitute (Moderate)
    • 4.3.5. Rivalry Among The Existing Competitors (Moderate)
  • 4.4. PESTLE Analysis
  • 4.5. Gout Therapeutics Market Industry trends
    • 4.5.1. Newer treatments for gout
  • 4.6. Competitive Ranking Analysis

Chapter 5. Gout Therapeutics Market Assessment by Drug Class

  • 5.1. KEY FINDINGS
  • 5.2. Introduction
    • 5.2.1. Global Gout Therapeutics Market, By Type, 2015 - 2026 (USD Million)
  • 5.3. Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 5.3.1. Global Gout Therapeutics NSAIDs Market, by Region, 2015-2026 (USD Million)
    • 5.3.2. North America: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
    • 5.3.3. Europe: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
    • 5.3.4. Asia-Pacific: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
    • 5.3.5. LATAM: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
    • 5.3.6. MEA: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
  • 5.4. Corticosteroids
    • 5.4.1. Global Gout Therapeutics Corticosteroids Market, by Region, 2015-2026 (USD Million)
    • 5.4.2. North America: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
    • 5.4.3. Europe: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
    • 5.4.4. Asia-Pacific: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
    • 5.4.5. LATAM: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
    • 5.4.6. MEA: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
  • 5.5. Colchicine
    • 5.5.1. Global Gout Therapeutics Colchicine Market, by Region, 2015-2026 (USD Million)
    • 5.5.2. North America: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
    • 5.5.3. Europe: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
    • 5.5.4. Asia-Pacific: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
    • 5.5.5. LATAM: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
    • 5.5.6. MEA: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
  • 5.6. Urate Lowering Agents
    • 5.6.1. Global Gout Therapeutics Urate Lowering Agents Market, by Region, 2015-2026 (USD Million)
    • 5.6.2. North America: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
    • 5.6.3. Europe: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
    • 5.6.4. Asia-Pacific: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
    • 5.6.5. LATAM: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
    • 5.6.6. MEA: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)

Chapter 6. Gout Therapeutics Market Assessment by Disease Condition

  • 6.1. KEY FINDINGS
  • 6.2. Introduction
    • 6.2.1. Global Gout Therapeutics Market, By Disease Condition, 2015 - 2026 (USD Million)
  • 6.3. Acute Gout
    • 6.3.1. Global Acute Gout Therapeutics Market, by Region, 2015-2026 (USD Million)
    • 6.3.2. North America: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 6.3.3. Europe: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 6.3.4. Asia-Pacific: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 6.3.5. LATAM: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 6.3.6. MEA: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • 6.4. Chronic
    • 6.4.1. Global Chronic Gout Therapeutics Market, by Region, 2015-2026 (USD Million)
    • 6.4.2. North America: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 6.4.3. Europe: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 6.4.4. Asia-Pacific: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 6.4.5. LATAM: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 6.4.6. MEA: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)

Chapter 7. Gout Therapeutics Market Assessment by Geography

  • 7.1. KEY FINDINGS
  • 7.2. Introduction
    • 7.2.1. Gout Therapeutics Market Assessment, By Geography, 2015-2026 (USD Million)
  • 7.3. NORTH AMERICA
    • 7.3.1. North America: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 7.3.2. North America: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
    • 7.3.3. North America: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.3.4. U.S.
      • 7.3.4.1. U.S.: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.3.4.2. U.S.: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.3.5. Canada
      • 7.3.5.1. Canada: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.3.5.2. Canada: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • 7.4. EUROPE
    • 7.4.1. Europe: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 7.4.2. Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
    • 7.4.3. Europe: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.4.4. Germany
      • 7.4.4.1. Germany: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.4.4.2. Germany: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.4.5. UK
      • 7.4.5.1. UK: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.4.5.2. UK: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.4.6. France
      • 7.4.6.1. France: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.4.6.2. France: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.4.7. Italy
      • 7.4.7.1. Italy: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.4.7.2. Italy: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.4.8. Spain
      • 7.4.8.1. Spain: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.4.8.2. Spain: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.4.9. Belgium
      • 7.4.9.1. Belgium: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.4.9.2. Belgium: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.4.10. Rest of Europe
      • 7.4.10.1. Rest of Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.4.10.2. Rest of Europe: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • 7.5. ASIA-PACIFIC
    • 7.5.1. Asia Pacific: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 7.5.2. Asia Pacific: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
    • 7.5.3. Asia Pacific: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.5.4. China
      • 7.5.4.1. China: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.5.4.2. China: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.5.5. India
      • 7.5.5.1. India: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.5.5.2. India: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.5.6. Japan
      • 7.5.6.1. Japan: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.5.6.2. Japan: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. South Korea: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.5.7.2. South Korea: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.5.8. Australia
      • 7.5.8.1. Australia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.5.8.2. Australia: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.5.9. Rest of APAC
      • 7.5.9.1. Rest of APAC: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.5.9.2. Rest of APAC: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • 7.6. LATIN AMERICA
    • 7.6.1. Latin America: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 7.6.2. Latin America: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
    • 7.6.3. Latin America: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.6.4. Brazil
      • 7.6.4.1. Brazil: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.6.4.2. Brazil: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.6.5. Mexico
      • 7.6.5.1. Mexico: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.6.5.2. Mexico: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.6.6. Rest of LATAM
      • 7.6.6.1. Rest of LATAM: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.6.6.2. Rest of LATAM: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • 7.7. MIDDLE EAST AND AFRICA
    • 7.7.1. Middle East & Africa: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
    • 7.7.2. Middle East & Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
    • 7.7.3. Middle East & Africa: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.7.4. South Africa
      • 7.7.4.1. South Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.7.4.2. South Africa: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.7.5. Saudi Arabia
      • 7.7.5.1. Saudi Arabia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.7.5.2. Saudi Arabia: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
    • 7.7.6. Rest of Middle East and Africa
      • 7.7.6.1. Rest of MEA: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
      • 7.7.6.2. Rest of MEA: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Agreements, Collaborations, Product Developments and launch Analysis
    • 8.1.1. Strategic Analysis - Gout Therapeutics Market
  • 8.2. Prouct/Service Launch
  • 8.3. Partnerships/Collaborations/Agreements
  • 8.4. Approvals
  • 8.5. Others

Chapter 9. Company Profiles

  • 9.1. AstraZeneca
    • 9.1.1. Business Overview
    • 9.1.2. Financial Snapshot
    • 9.1.3. Products and Services
    • 9.1.4. Recent Developments
  • 9.2. Horizon Pharma Plc
    • 9.2.1. Business Overview
    • 9.2.2. Financial Snapshot
    • 9.2.3. Products and Services
    • 9.2.4. Recent Developments
  • 9.3. Takeda Pharmaceutical Company Limited
    • 9.3.1. Business Overview
    • 9.3.2. Financial Snapshot
    • 9.3.3. Products and Services
    • 9.3.4. Recent Developments
  • 9.4. GlaxoSmithKline plc
    • 9.4.1. Business Overview
    • 9.4.2. Financial Snapshot
    • 9.4.3. Products and Services
    • 9.4.4. Recent Developments
  • 9.5. Novartis AG
    • 9.5.1. Business Overview
    • 9.5.2. Financial Snapshot
    • 9.5.3. Products and Services
    • 9.5.4. Recent Developments
  • 9.6. Merck & Co. Inc.
    • 9.6.1. Business Overview
    • 9.6.2. Financial Snapshot
    • 9.6.3. Products and Services
    • 9.6.4. Recent Developments
  • 9.7. Teijin Pharma Limited
    • 9.7.1. Business Overview
    • 9.7.2. Financial Snapshot
    • 9.7.3. Products and Services
    • 9.7.4. Recent Developments
  • 9.8. Regeneron Pharmaceuticals, Inc.
    • 9.8.1. Business Overview
    • 9.8.2. Financial Snapshot
    • 9.8.3. Products and Services
    • 9.8.4. Recent Developments
  • 9.9. Ironwood Pharmaceuticals, Inc.
    • 9.9.1. Business Overview
    • 9.9.2. Financial Snapshot
    • 9.9.3. Products and Services
    • 9.9.4. Recent Developments
  • 9.10. JW Pharmaceutical
    • 9.10.1. Business Overview
    • 9.10.2. Financial Snapshot
    • 9.10.3. Products and Services
    • 9.10.4. Recent Developments
  • 9.11. Selecta Biosciences, Inc.
    • 9.11.1. Business Overview
    • 9.11.2. Financial Snapshot
    • 9.11.3. Products and Services
    • 9.11.4. Recent Developments
  • 9.12. Grunenthal Group
    • 9.12.1. Business Overview
    • 9.12.2. Financial Snapshot
    • 9.12.3. Products and Services
    • 9.12.4. Recent Developments

List of Tables

  • Table 1 Drivers and Inhibitors For Global Market
  • Table 2 Restraints Global Market
  • Table 3 Global Gout Therapeutics Market, By Type, 2015 - 2026 (USD Million)
  • Table 4 Global Gout Therapeutics NSAIDs Market, by Region, 2015-2026 (USD Million)
  • Table 5 North America: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
  • Table 6 Europe: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
  • Table 7 Asia-Pacific: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
  • Table 8 LATAM: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
  • Table 9 MEA: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
  • Table 10 Global Gout Therapeutics Corticosteroids Market, by Region, 2015-2026 (USD Million)
  • Table 11 North America: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
  • Table 12 Europe: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
  • Table 13 Asia-Pacific: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
  • Table 14 LATAM: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
  • Table 15 MEA: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
  • Table 16 Global Gout Therapeutics Colchicine Market, by Region, 2015-2026 (USD Million)
  • Table 17 North America: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
  • Table 18 Europe: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
  • Table 19 Asia-Pacific: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
  • Table 20 LATAM: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
  • Table 21 MEA: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
  • Table 22 Global Gout Therapeutics Urate Lowering Agents Market, by Region, 2015-2026 (USD Million)
  • Table 23 North America: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
  • Table 24 Europe: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
  • Table 25 Asia-Pacific: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
  • Table 26 LATAM: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
  • Table 27 MEA: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
  • Table 28 Global Gout Therapeutics Market, By Deployment Model, 2015 - 2026 (USD Million)
  • Table 29 Global Acute Gout Therapeutics Market, by Region, 2015-2026 (USD Million)
  • Table 30 North America: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 31 Europe: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 32 Asia-Pacific: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 33 LATAM: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 34 LATAM: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 35 Global Chronic Gout Therapeutics Market, by Region, 2015-2026 (USD Million)
  • Table 36 North America: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 37 Europe: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 38 Asia-Pacific: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 39 LATAM: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 40 MEA: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 41 Gout Therapeutics Market Assessment, By Geography, 2015-2026 (USD Million)
  • Table 42 North America: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 43 North America: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 44 North America: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 45 U.S.: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 46 U.S.: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 47 Canada: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 48 Canada: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 49 Europe: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 50 Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 51 Europe: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 52 Germany: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 53 Germany: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 54 UK: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 55 UK: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 56 France: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 57 France: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 58 Italy: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 59 Italy: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 60 Spain: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 61 Spain: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 62 Belgium: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 63 Belgium: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 64 Rest of Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 65 Rest of Europe: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 66 Asia-Pacific: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
  • Table 67 Asia-Pacific: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 68 Asia-Pacific: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 69 China: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 70 China: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 71 India: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 72 India: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 73 Japan: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 74 Japan: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 75 South Korea: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 76 South Korea: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 77 Australia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 78 Australia: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 79 RoAPAC: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 80 RoAPAC: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 81 LATAM: Gout Therapeutics Market, By Country, 2015-2026 (USD Million)
  • Table 82 LATAM: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 83 LATAM: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 84 Brazil: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 85 Brazil: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 86 Mexico: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 87 Mexico: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 88 RoLATAM: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 89 RoLATAM: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 90 Middle East and Africa: Gout Therapeutics Market, By Country, 2015-2026 (USD Million)
  • Table 91 Middle East and Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 92 Middle East and Africa: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 93 South Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 94 South Africa: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 95 Saudi Arabia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 96 Saudi Arabia: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
  • Table 97 RoMEA: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
  • Table 98 RoMEA: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)

List of Figures

  • Figure 1. Market Highlights
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top Down Approach
  • Figure 4. Research Methodology: Bottom Up Approach
  • Figure 5. Market by Geography
  • Figure 6. Gout Therapeutics Market - Drivers and Opportunities, Restraints and Challenges
  • Figure 7. Porter's Five Forces
  • Figure 8. Market by Type
  • Figure 9. Global Gout Therapeutics Market, By Type, 2020 - 2026 (USD Million)
  • Figure 10. Market by Disease Condition
  • Figure 11. Global Gout Therapeutics Market, By Disease Condition, 2020 - 2026 (USD Million)
  • Figure 12. Gout Therapeutics Market Assessment, By Geography, 2020-2026 (USD Milliom)
  • Figure 13. Strategic Analysis - Gout Therapeutics Market